Video

Dr. Hsieh on Unmet Needs of Rare Kidney Cancer Variants

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

James J. Hsieh, MD, PhD, professor of medicine, Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses unmet needs in non-clear cell renal cell carcinoma (RCC).

Over the past 15 years, clear cell RCC has gained 15 novel treatments that target 7 different mechanisms, says Hsieh. These options have led to increased survival for these patients who make up the majority of kidney cancers.

However, little progress has been made in non-clear cell RCC, Hsieh says. Due to the rarity of non-clear cell RCC, it is difficult to enroll patients on clinical trials. As a result, little progress has been made in this group of patients with a relatively poor prognosis.

Hsieh hopes that clinical trials will expand to non-clear cell RCC, so the field can work toward better understanding the mechanisms of the disease and improving patient outcomes.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center